Suche
Mein Konto
Breakthrough in the fight against salmonella: new substance C26 discovered!
Research at the University of Tübingen discovers substance C26, which inhibits salmonella infections and enables new therapies.
Breakthrough in the fight against salmonella: new substance C26 discovered!
A research team from University of Tübingen and the German Center for Infection Research has discovered a novel substance called C26 that inhibits the signaling chains of Salmonella during their cell invasion. This discovery could be crucial to stopping salmonella infections early, before the bacteria invade tissue.
The project was led by Professor Samuel Wagner from the CMFI Cluster of Excellence. The results were recently published in the scientific journalScience Advancespublished. Salmonella is responsible for over 16 to 33 million infections worldwide and between 500,000 and 600,000 deaths annually, highlighting the urgent need for new therapeutic approaches. Given the growing resistance to many antibiotics, the development of alternative treatment options is essential.
How C26 works
C26 shows promising activity by binding to the HilD regulator, which is central to Salmonella entry into host cells. This binding disrupts the function of the regulator, which can significantly affect the pathogenicity of the bacteria in macrophages. In addition, C26 has a specific effect on salmonella and has no negative influence on the human microbiome.
The development of pathoblockers such as C26 may represent a safer and more effective treatment strategy in the future. Unlike traditional antibiotics, these new drugs could have fewer negative effects on the body. The development of additional medications for animals, especially poultry, is a particular focus of research.
The challenges of combating salmonella
Controlling Salmonella is complicated by its ability to develop resistance to antimicrobials. In addition to classic hereditary resistance, non-hereditary resistance, such as biofilms and persistence cells, play a crucial role in persistent infections. The WHO even put salmonella on the priority list for the development of new antimicrobials in 2017.
Looking at the economics, salmonellosis losses in the United States exceed $3.5 billion annually. In the EU, 94,530 deaths from salmonella were reported in 2016, illustrating the scale of the problem. To overcome these challenges, scientists are working on various strategies, such as targeting the MlaABC system to improve antibiotic penetration and reduce biofilm formation. Probiotics as well as predatory bacteria have also emerged as potential solutions to combat Salmonella.
Given the global threat of salmonella infections and increasing antibiotic resistance, research into new therapeutic approaches is more urgent than ever. The identification and development of substances such as C26 may hold the key to more effective treatment methods and could therefore represent a significant advance in the fight against Salmonella.